Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

IGF-1 LR3 Cycle Length: Protocol Comparison

Cycle design determines whether you observe reproducible anabolic signaling or progressive receptor desensitization. The following comparison shows four common cycle structures and their biological trade-offs. Short Cycle (2 weeks on, 2 weeks off) 14 days Days

This comparison does not assign a generated winner or score.

  • Cycle design determines whether you observe reproducible anabolic signaling or progressive receptor desensitization. The following comparison shows four common cycle structures and their biological trade-offs.
  • Short Cycle (2 weeks on, 2 weeks off)
  • 14 days
  • Days 5–14
  • Minimal. Stops before significant downregulation
  • Excellent. Maintains receptor sensitivity across 4+ cycles
  • Best for multi-cycle research designs requiring consistent response magnitude across multiple iterations. Sacrifices cumulative exposure for repeatability.
  • Standard Cycle (3 weeks on, 3 weeks off)
  • 21 days
  • Days 7–21
  • Low. Exits just as downregulation begins
  • Very good. Preserves 80–85% receptor density between cycles
  • Optimal for most research applications. Balances cumulative anabolic exposure with receptor preservation. Gold standard for controlled studies.
  • Extended Cycle (4 weeks on, 4 weeks off)
  • 28 days
  • Days 7–24
  • Moderate. Enters downregulation curve but exits before severe adaptation
  • Good. Requires strict washout adherence to maintain efficacy
  • Acceptable when research timeline justifies maximum single-cycle exposure. Last 7 days show diminishing marginal returns.
  • Prolonged Cycle (6 weeks on, 6 weeks off)
  • 42 days
  • 42 days minimum (8 weeks preferred)
  • Days 7–28
  • High. Significant receptor downregulation by day 35+
  • Poor. Second cycle produces 30–40% weaker response even with 6-week washout
  • Not recommended except in single-cycle terminal studies. Extends washout requirements and compromises future cycle efficacy.
More references

Related material